Zoetis Inc. which can be found using ticker (ZTS) now have 15 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $248.00 and $172.12 with the average share target price sitting at $218.58. (at the time of writing). Now with the previous closing price of $181.50 this would imply there is now a potential upside of 20.4%. The day 50 moving average is $189.10 and the 200 day MA is $179.69. The company has a market capitalization of 85.62B. Currently the stock stands at: $180.01 USD
The potential market cap would be $103,114,497,504 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 35.37, revenue per share of $19.46 and a 14.41% return on assets.
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.
